fda semaglutide shortage resolved 2025 announcement FDA: Ozempic and Wegovy drug is over New project announcement: HHS‑OIG is

Semaglutide (Wegovy): STEP-1 trial The once-weekly injectable semaglutide 2.4 mg is currently the market leader for pharmacologic weight management

CJC-1295 has become one of the latest wellness obsessions, popping up in conversations about longevity, body composition, energy, recovery, and healthy aging

Tirzepatide may benefit patients seeking maximal metabolic effect, those with weight-loss plateaus on semaglutide, or individuals whose genetic profile suggests favorable GIP pathway response

USA 100 , 63586363 (2003)

This makes it a compelling non-surgical option for patients seeking joint and soft tissue support, particularly for conditions like knee pain